| Jorge Juan Arango, MD | |
|
5959 Gateway Blvd W Ste 104, El Paso, TX 79925-3315 | |
| (915) 779-5866 | |
| (915) 771-6558 |
| Full Name | Jorge Juan Arango |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 29 Years |
| Location | 5959 Gateway Blvd W Ste 104, El Paso, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326081795 | NPI | - | NPPES |
| 118689202 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | J0905 (Texas) | Primary |
| Entity Name | El Paso Ear Nose & Throat Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083646053 PECOS PAC ID: 7012088982 Enrollment ID: O20080619000727 |
News Archive
Researchers at the American Society of Gene Therapy Meeting in St. Louis announced that by using imaging technologies, they are able to successfully trace the delivery of DNA nanoparticles and the extent of gene transfer in the lungs of cystic fibrosis (CF) animals.
An article published in this month's New England Journal of Medicine suggests that the best way to avoid infection from mosquito bites is to actually flick them away rather than squashing them into the skin.
Agile Therapeutics, Inc., a pharmaceutical development company specializing in women's healthcare products, today announced study initiation and dosing of the first patient in the Company's pivotal, Phase 3 NEW CHOICE Study of AG200-15, Agile's lead contraceptive patch. AG200-15 is designed to effectively deliver a low dose of estrogen in combination with levonorgestrel. The patch is applied once weekly for three weeks followed by a patch-free week.
Merck, known outside the United States and Canada as MSD, and ARIAD Pharmaceuticals, Inc.,, today announced the presentation of detailed results from the Phase III SUCCEED clinical trial. SUCCEED evaluated oral ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy.
Genes that drive the shape of human noses have been identified by a UCL-led study. The four genes mainly affect the width and 'pointiness' of noses which vary greatly between different populations. The new information adds to our understanding of how the human face evolved and may help contribute to forensic DNA technologies that build visual profiles based on an individual's genetic makeup.
› Verified 5 days ago
| Entity Name | Jorge J Arango Md Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649811332 PECOS PAC ID: 7719218536 Enrollment ID: O20191009002022 |
News Archive
Researchers at the American Society of Gene Therapy Meeting in St. Louis announced that by using imaging technologies, they are able to successfully trace the delivery of DNA nanoparticles and the extent of gene transfer in the lungs of cystic fibrosis (CF) animals.
An article published in this month's New England Journal of Medicine suggests that the best way to avoid infection from mosquito bites is to actually flick them away rather than squashing them into the skin.
Agile Therapeutics, Inc., a pharmaceutical development company specializing in women's healthcare products, today announced study initiation and dosing of the first patient in the Company's pivotal, Phase 3 NEW CHOICE Study of AG200-15, Agile's lead contraceptive patch. AG200-15 is designed to effectively deliver a low dose of estrogen in combination with levonorgestrel. The patch is applied once weekly for three weeks followed by a patch-free week.
Merck, known outside the United States and Canada as MSD, and ARIAD Pharmaceuticals, Inc.,, today announced the presentation of detailed results from the Phase III SUCCEED clinical trial. SUCCEED evaluated oral ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy.
Genes that drive the shape of human noses have been identified by a UCL-led study. The four genes mainly affect the width and 'pointiness' of noses which vary greatly between different populations. The new information adds to our understanding of how the human face evolved and may help contribute to forensic DNA technologies that build visual profiles based on an individual's genetic makeup.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jorge Juan Arango, MD 5959 Gateway Blvd W Ste 104, El Paso, TX 79925-3315 Ph: (915) 779-1716 | Jorge Juan Arango, MD 5959 Gateway Blvd W Ste 104, El Paso, TX 79925-3315 Ph: (915) 779-5866 |
News Archive
Researchers at the American Society of Gene Therapy Meeting in St. Louis announced that by using imaging technologies, they are able to successfully trace the delivery of DNA nanoparticles and the extent of gene transfer in the lungs of cystic fibrosis (CF) animals.
An article published in this month's New England Journal of Medicine suggests that the best way to avoid infection from mosquito bites is to actually flick them away rather than squashing them into the skin.
Agile Therapeutics, Inc., a pharmaceutical development company specializing in women's healthcare products, today announced study initiation and dosing of the first patient in the Company's pivotal, Phase 3 NEW CHOICE Study of AG200-15, Agile's lead contraceptive patch. AG200-15 is designed to effectively deliver a low dose of estrogen in combination with levonorgestrel. The patch is applied once weekly for three weeks followed by a patch-free week.
Merck, known outside the United States and Canada as MSD, and ARIAD Pharmaceuticals, Inc.,, today announced the presentation of detailed results from the Phase III SUCCEED clinical trial. SUCCEED evaluated oral ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy.
Genes that drive the shape of human noses have been identified by a UCL-led study. The four genes mainly affect the width and 'pointiness' of noses which vary greatly between different populations. The new information adds to our understanding of how the human face evolved and may help contribute to forensic DNA technologies that build visual profiles based on an individual's genetic makeup.
› Verified 5 days ago
Marino A Rios, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 1714 N Mesa, El Paso, TX 79902 Phone: 915-533-1626 Fax: 915-533-1641 | |
Dr. Benjamin James Westbrook, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1500 N Mesa St, El Paso, TX 79902 Phone: 915-532-6935 Fax: 915-532-6289 | |
Dr. Roger Glynn Skiles, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 4801 Alberta Ave, El Paso, TX 79905 Phone: 915-215-5300 Fax: 915-215-8606 | |
Dr. Jorge Ivan Contreras, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 5959 Gateway Blvd W, 160, El Paso, TX 79925 Phone: 915-779-1716 | |
Eric M Gross, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2400 Trawood Dr Ste 304, El Paso, TX 79936 Phone: 915-591-8400 Fax: 915-591-8401 | |
Dr. Tyler Swiss, DO Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 5005 N Piedras St, El Paso, TX 79920 Phone: 915-742-3450 | |
Miller Franklin Rhodes, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 4801 Alberta Ave., El Paso, TX 79905 Phone: 915-545-7507 Fax: 915-545-9799 |